Alkermes plc

Financials

Flusso di cassa derivante dalle attività operative 82.84 M101.72 M21.04 M401.35 M439.12 M520.75 M 520.75 M Flussi di cassa derivanti dalle attività di investimento -11.48 M-66.2 M-64.54 M53.36 M-111.31 M295.5 M 295.5 M Liquidità derivante dalle attività di finanziamento -2.17 M29.07 M-1.57 M-289.71 M-494.14 M12.38 M 12.38 M Liquidità libera 40.62 M73.69 M-17.21 M353.31 M405.64 M480.33 M 480.33 M

Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.

ALKS

Financials

Alkermes plc

Notizie

Alkermes pubblica studio di 56 settimane su sintomi negativi di Lybalvi

Mizuho alza il target su Alkermes a $53 per fiducia nel farmaco

Le azioni Alkermes raggiungono il massimo a 52 settimane a 36,46$

Top 2 Health Care Stocks That May Implode In April - Alkermes (NASDAQ:ALKS), Assertio Hldgs (NASDAQ:ASRT)

Eli Lilly To Buy Centessa Pharma For Up To $7.8 Billion; Centessa Shares Skyrocket

Azioni Alkermes in rialzo del 13% dopo accordo con Lilly sui disturbi del sonno

Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet

Why Is Alkermes (ALKS) Down 2.6% Since Last Earnings Report?

Piper Sandler riduce il target di prezzo di Alkermes per maggiori spese in R&S

Tracking Baker Brothers Portfolio – Q4 2025 Update (NASDAQ:INCY)

New Strong Sell Stocks for March 11th

Truist conferma Buy su Alkermes, vede rialzo dai dati